Coronavirus

COVID-19 patients treated with fluvoxamine had a reduced risk of hospitalization and death.

Most COVID-19 infection occurs in household settings, and though vaccinated individuals who contracted the Delta variant recovered more quickly than unvaccinated persons, they had similar peak viral load.

The new AY.4.2 "Delta plus" COVID-19 variant is gaining prevalence abroad and is estimated to be slightly more transmissible.

A new study assessed the vaccine acceptance and access among Black and Latinx communities.

First responders are twice as likely to become infected with COVID-19 in the workplace as health care workers and other essential workers, and this increases significantly after adjusting for cofounding factors.

The World Health Organization's (WHO) newly formed Scientific Advisory Group on the Origins of Novel Pathogens (SAGO) will lay the groundwork for future identification of future disease threats.

St. Joseph Mercy Health System launched a program in February to provide infusion of monoclonal antibodies for COVID-19 in patients’ homes.

This recommendation was based off of data showing the vaccine was 90% efficacious in this population, and sets the stage for the first COVID-19 vaccine in the age group.

The committee is meeting today to review the data presented to them, and will vote to either recommend or not an Emergency Use Authorization in this pediatric population.

Investigators retrospectively observed 2 communities of essential workers in Toronto, Canada.

Unpublished data from the company's ongoing pediatric trial show children aged 6 to <12 years old have an antibody response greater than that of young adults.

The median vaccination rate of white American adults was found to be 1.3 times higher than Black and Hispanic adults.

Data presented to the Vaccines and Related Biological Products Advisory Committee (VRBPAC) showed 2 10 µg doses of the Pfizer-BioNTech vaccine to be 90.7% effective in children older than 5 and younger than 12.

The federal agency and infectious disease organization have teamed up to offer a wealth of resources for health care professionals on the frontlines of treating the virus.

The FDA and CDC have authorized and recommended 3 different booster doses, to be used in "mix-and-match" strategy among eligible adults. What does this mean for immunity?

The Centers for Disease Control and Prevention (CDC) Director Rochelle Walensky's, MD, endorsement Thursday evening came after 2 days of deliberation from the CDC’s Advisory Committee on Immunization Practices (ACIP) where the group recommended the Moderna and Janssen COVID-19 vaccine “booster” doses.

The actions taken by the FDA set differing availability of the 3 emergency-authorized vaccines.

PASC (postacute sequelae of COVID-19) was found to persist for at least 6 months in more than half of those contracting the infection.

The CDC found 2 doses of Pfizer-BioNTech reduced COVID-19 severe outcomes and hospitalization by 93% in adolescents 12-18 years old.

The White House said it has secured enough of the Pfizer-BioNTech vaccine supply to offer vaccinations for everyone in this age group.

The company announced the Emergency Use Authorization (EUA) for use with its Spectrum Solutions SpectrumDNA SDNA-1000 collection device on the Amplitude Solution.

The company’s current investigational medical device, Sigyn Therapy, is a novel medical device that is being studied for addressing viral pathogens and bacterial toxins to avoid this massive inflammation onslaught and the potential of sepsis.

Infants, children, and adolescents can carry and spread COVID-19 at the same rate as adults.

The decision comes after supporting data from a "mix and match" trial last week, and may align with emergency authorizations for the Moderna and Janssen booster doses.

One of the infrequently discussed health outcomes that can be impacted by a pandemic is fertility. Using a cross-sectional study, a research team reported incremental increases in infertility during this period.

Comparing 2020 to 2019, investigators saw a reduction in the number of HIV tests, the number of in-person consultations, and new enrollments in care, due to the disruption in HIV care throughout the COVID-19 pandemic.

The VRBPAC committee unanimously voted in favor of the Janssen (Johnson & Johnson) COVID-19 vaccine for use under EUA as a booster dose in individuals 18 years and older at least 2 months after a single dose primary vaccination.

Outside of vaccines, these underutilized therapies are the best defense against severe disease.

Lower rates of COVID-19 vaccination may be due to access, not hesitancy.

The VRBPAC meeting precedes deliberation from the FDA on amending the company's emergency authorization to include booster doses for adult patients.